PharmaShots Weekly | Oct 05, 2026 Edition

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

Dosing Frequency Innovation: The collaboration targets monthly and quarterly dosing profiles for peptide-based cardiometabolic injectables, potentially reducing administration frequency from the current weekly standard for drugs like semaglutide.

•

Platform Validation: The up to EUR 1.165 billion potential value validates Nanexa's PharmaShell ALD platform beyond its earlier Moderna mRNA collaboration, demonstrating applicability across multiple therapeutic modalities.

•

Competitive Positioning: The deal supports Novo's efforts to close the gap to rivals in the cardiometabolic arena by advancing longer-lasting injectable formulations that could improve patient convenience and adherence.

•

Five-Program Scope: The agreement covers up to five development programs spanning obesity, type 2 diabetes and other cardiometabolic diseases, with the specific Novo products to be developed not disclosed.

•

ALD Technology Application: PharmaShell uses atomic layer deposition to encapsulate active pharmaceutical ingredients with an ultra-thin inorganic coating, enabling precise, controlled and sustained release of the API over extended periods.

•

Development Leadership: Novo will lead all subsequent global development and commercialization activities, leveraging its established expertise in obesity and type 2 diabetes treatments while Nanexa provides the drug delivery platform technology.

•

KRAS G12D Targeting: SPR2015 targets KRAS G12D, one of the most common oncogenic KRAS mutations found in human cancers including pancreatic, colorectal, and lung tumors, where the glycine-to-aspartate substitution locks signaling in an active state.

•

Molecular Glue Mechanism: The compound functions as an ON-state molecular glue inhibitor, engaging the active GTP-bound form of mutant KRAS through a tri-complex with cyclophilin A, representing a differentiated approach from conventional orthosteric inhibitors.

•

Preclinical Premium Valuation: The $400 million upfront and up to $2.13 billion total potential value reflects premium valuations for differentiated RAS-pathway assets even at the preclinical stage, underscoring the high unmet medical need in KRAS-mutant cancers.

•

Worldwide Rights: The agreement grants Merck exclusive global rights to develop, manufacture, and commercialize SPR2015, not an ex-China split, providing full control over the asset's development trajectory and commercial potential.

•

Multi-Indication Potential: Milestone payments are structured across multiple indications, reflecting the broad applicability of KRAS G12D inhibition across pancreatic, colorectal, lung and other tumor types where this mutation is prevalent.

•

Pipeline Diversification: The acquisition strengthens Merck's oncology pipeline with a differentiated KRAS G12D inhibitor, complementing existing precision medicine candidates and expanding the company's RAS-pathway targeting capabilities.

•

Strategic Validation: The $2 billion investment from AstraZeneca provides external validation of Summit's ivonescimab program and the broader strategy of combining PD-1/VEGF bispecific antibodies with ADCs across multiple tumor types.

•

ADC Combination Strategy: The collaboration focuses on combining ivonescimab with AstraZeneca's ADC portfolio, particularly sonesitatug vedotin targeting CLDN18.2, reflecting the industry trend toward bispecific-ADC combinations in oncology.

•

Capital Strengthening: The investment significantly bolsters Summit's balance sheet, with proceeds expected to fund ongoing phase 3 trials of ivonescimab across eight tumor types and support the expanding combination development program.

•

Binding vs. Non-Binding Components: Only the sonesitatug vedotin plus ivonescimab GI cancer collaboration is a binding agreement, while the broader MOU covering additional AZ cancer medicines including ADCs is non-binding with no assurance of future collaboration.

•

Cost-Sharing Structure: Under both the binding clinical collaboration and the non-binding MOU, the companies intend to share clinical development costs while each retains rights to its respective assets, avoiding cross-licensing or commercial rights transfers.

•

Equity Stake Without Control: The preferred shares are convertible to approximately 12% of Summit's outstanding common stock post-conversion, providing AstraZeneca with significant economic exposure and alignment without operational control over Summit's programs.

•

Oral Weekly Innovation: HRS-1596's potential for once-weekly oral dosing would represent a significant advancement over current daily oral GLP-1 therapies and could improve patient convenience and adherence in obesity and type 2 diabetes treatment.

•

China Outbound Licensing: The $2.6 billion deal represents a landmark outbound licensing transaction for China's largest innovative pharma company in the highly competitive GLP-1 market, validating Chinese biotech innovation in cardiometabolic diseases.

•

Dual Agonist Strategy: The GLP-1/GIP dual receptor agonist mechanism follows the success of tirzepatide (Mounjaro/Zepbound), leveraging dual incretin pathway activation for enhanced efficacy in weight loss and glycemic control.

•

Geographic Rights Split: Novo obtains exclusive global rights outside Greater China (mainland China, Hong Kong SAR, Macao SAR, and Taiwan), while Hengrui retains development and commercialization rights in the Chinese market. 1326

•

Phase 1-Ready Asset: HRS-1596 is positioned as phase I-ready with Chinese regulatory clearance already obtained, enabling Novo to initiate clinical development promptly following deal closure in Q4 2026.

•

Milestone-Heavy Economics: The deal structure features a $300 million upfront payment with up to $2.3 billion in contingent milestone payments tied to development, regulatory, and commercial achievements, plus net sales-based royalties.

•

Thymus Platform Expansion: The TLB-33 acquisition strengthens Tolerance Bio's thymus-focused pipeline with a complementary mechanism targeting IL-33, an immune mediator linked to thymic dysfunction and age-related immune decline.

•

Clinical-Stage Asset: TLB-33 has already been evaluated in over 150 patients across five clinical trials by Tanabe, de-risking the asset compared to earlier-stage candidates and enabling Tolerance to advance directly to phase 2 development.

•

Strategic Partnership Model: The deal structure combines milestone payments, equity consideration, and tiered royalties, aligning Tanabe's financial interests with Tolerance's development success while providing Tolerance with full ex-Japan commercialization control.

•

Geographic Rights Split: Tolerance Bio obtains worldwide development and manufacturing rights plus exclusive commercialization rights outside Japan, while Tanabe retains commercialization rights in its home Japanese market, aligning with Tanabe's Japan-focused strategy.

•

Multi-Indication Potential: The license covers all indications, enabling Tolerance to explore TLB-33 across thymic preservation, immune resilience, and additional immune-mediated diseases beyond Tanabe's initial clinical focus.

•

Phase 2 Development Plan: Tolerance plans to initiate phase 2 clinical development of TLB-33 to assess its use for thymic preservation and broader immune resilience, building on Tanabe's existing clinical data package from five prior trials.

•

Design: Randomized, active‑controlled, non‑inferiority trial with parallel investigational arms.

•

Comparator: Aflibercept 2 mg Q8W after loading.

•

Primary endpoint: Non‑inferiority in change in best‑corrected visual acuity (BCVA) from baseline to the average of Weeks 40, 44 and 48 (Year 1).

•

Retreatment criteria: Strict "treat‑to‑dryness" criteria were applied to assess durability.

•

Met the primary endpoint (p=0.0007), demonstrating non‑inferior vision gains vs aflibercept at Year 1.

•

Showed rapid and sustained retinal drying, with strong immediacy of effect matching/exceeding aflibercept through the loading phase.

•

Durability: 54% of patients achieved a 6‑month dosing interval at Year 1 under strict treat‑to‑dryness criteria.

•

Met the vision primary endpoint (p=0.0036), demonstrating non‑inferior BCVA gains vs aflibercept at Year 1.

•

Met a key anatomical secondary endpoint (p<0.0001), supporting robust drying and disease control.

•

Zenkuda: 0% IOI; cataract adverse events 0.5% (vs 0.9% with aflibercept).

•

Tabirafusp‑ted: 0.4% IOI; cataract adverse events 0% (vs 0.9% with aflibercept).

•

Zenkuda BLA: Kodiak plans to submit a multi‑indication BLA for Zenkuda in Q4 2026, based on five positive Phase 3 studies: DAYBREAK and DAYLIGHT (wAMD), GLOW and GLOW2 (diabetic retinopathy), and BEACON (macular edema following retinal vein occlusion).

•

Tabirafusp‑ted: Post‑hoc analyses are planned to identify wAMD subgroups that may benefit from IL‑6 pathway inhibition. The Phase 3 ALTO study of tabirafusp‑ted in diabetic macular edema (DME) is currently enrolling.

•

Population: 1,152 adults with T2D and BMI ≥27 kg/m² (A1C ≥6.5% to ≤10.5%).

•

Intervention: Once‑weekly subcutaneous retatrutide 4 mg, 9 mg or 12 mg vs placebo for 80 weeks, using a stepwise dose‑escalation approach every 4 weeks.

•

Primary endpoint: Percent change in body weight from baseline to Week 80.investor.lilly+2

•

Mean weight reduction: 12.7% (4 mg), 19.1% (9 mg), 20.8% (12 mg) vs 4.0% with placebo.

•

≥15% weight loss: 36.6%, 62.2%, 67.0% vs 6.4%.

•

≥20% weight loss: 24.0%, 45.3%, 52.0% vs 1.5%.

•

≥25% weight loss: 10.8%, 30.6%, 34.9% vs 0.8%.

•

Mean A1C reduction: −1.4% (4 mg), −1.6% (9 mg), −1.5% (12 mg) vs −0.2% with placebo (baseline ~7.7%).

•

A1C ≤6.5%: 73.1%, 79.2%, 79.0% vs 26.3%.

•

A1C <5.7% (normoglycemia): 28.4%, 40.0%, 39.3% vs 4.4%.

•

Triglycerides: −39.5%

•

Non‑HDL cholesterol: −19.6%

•

Systolic blood pressure: −10.8 mmHg

•

Waist circumference: −16.9 cm

•

hsCRP (inflammation): −58.3%

•

Design: Randomized, double‑blind, active‑comparator Phase 3 trial (NCT06973291; TAK‑279 PsO 3004) in 606 adults.

•

Intervention: Zasocitinib 30 mg QD vs deucravacitinib 6 mg QD through Week 16.

•

Primary endpoint: PASI 100 (complete skin clearance) at Week 16.dermatologytimes+2

•

PASI 100: 36.5% with zasocitinib vs 13.9% with deucravacitinib (p<0.001); superiority observed as early as Week 8.

•

PASI 90: 62.5% vs 34.0% (p<0.001).

•

sPGA 0 (clear skin): 43.2% vs 18.5% (p<0.001).

•

Design: Pivotal, randomized, double‑blind, placebo‑ and active‑comparator-controlled Phase 3 trials (NCT06088043 and NCT06108544).

•

Focus: Durability through Week 52 and patient‑reported outcomes (itch, symptoms, quality of life).

•

Durability: Among Week 24 responders, up to ~93% maintained skin clearance through Week 52 (PsO 3001, post‑hoc) and through Week 40 (PsO 3002).

•

Itch & symptoms: Improvements in weekly mean PSSD itch and other symptom scores observed as early as Week 2 vs placebo (nominal p<0.001) and vs apremilast (nominal p<0.05 in PsO 3002).

•

Quality of life: Higher proportions achieved DLQI 0/1 (no impact on quality of life) by Week 4 vs placebo (nominal p<0.01 and p<0.001 in PsO 3001/3002) and vs apremilast (nominal p<0.01 in PsO 3002).

•

Population: Adults aged 18-75 years with a confirmed clinical diagnosis of DSWPD.

•

Intervention: Tasimelteon 20 mg PO QD vs placebo for 28 days.

•

Primary endpoint: Change in sleep onset time from baseline over the 28‑day treatment period, measured by sleep diary.

•

Mean shift in sleep onset: −42.5 minutes with tasimelteon vs −5.4 minutes with placebo.

•

Placebo‑adjusted difference: −37.1 minutes (p=0.022), meeting the primary endpoint.

•

≥30‑minute advance in sleep onset: 60% (12/20) with tasimelteon vs 15% (3/20) with placebo (p=0.008).

•

Mirum Pharmaceuticals and Incyte received US FDA approval for Atebrioz (zilurgisertib) to treat fibrodysplasia ossificans progressiva.

•

Eli Lilly received US FDA approval for Olumiant (baricitinib) to treat severe alopecia areata in pediatric patients.

•

AstraZeneca secured US FDA Priority Review for Imfinzi + enfortumab vedotin for muscle-invasive bladder cancer.

•

Innovent received NMPA approval for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

•

AbbVie received US FDA approval for Juvmo (tavapadon) to treat Parkinson's disease.

•

Teva received US FDA approval for Degevma, a biosimilar to Xgeva (denosumab).

•

Egetis Therapeutics received US FDA approval for Emcitate to treat MCT8 deficiency.

•

Meitheal Pharmaceuticals received US FDA approval for a high-concentration formulation of Yusimry, a biosimilar to Humira (adalimumab).

•

QIAGEN received US FDA clearance for the QIAstat-Dx BCID-GN Plus AMR Panel, a molecular diagnostic panel designed to detect bloodstream infections and key antimicrobial resistance markers.